Introducing REXULTI® (brexpiprazole): a new PBS-listed antipsychotic for schizophrenia

Por um escritor misterioso

Last updated 25 outubro 2024

Introducing REXULTI® (brexpiprazole): a new PBS-listed antipsychotic for schizophrenia

October 1^st sees the PBS listing of REXULTI, a novel antipsychotic indicated for the treatment of adults with schizophrenia.

Dichlorophenyl piperazines, including a recently-approved atypical antipsychotic, are potent inhibitors of DHCR7, the last enzyme in cholesterol biosynthesis. - Abstract - Europe PMC

Brexpiprazole - Mechanism of Action and Clinical Application

Dichlorophenyl piperazines, including a recently-approved atypical antipsychotic, are potent inhibitors of DHCR7, the last enzyme in cholesterol biosynthesis. - Abstract - Europe PMC

ex9902003.jpg

Full article: In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole

ex9901_img005.jpg

For Alzheimer's Agitation, Promising News from Rexulti (Brexpiprazole)

Michael Okun on X: Brexpiprazole (Rexulti) approved by FDA for #Alzheimers agitation. Will it find its way to #Parkinsons? Depends on if it makes motor symptoms significantly worse. It works on D2